vTv Therapeutics, JDRF partner for Phase 2 study of type 1 diabetes treatment
vTv Therapeutics announced that JDRF, the global organization funding type 1 diabetes research, will provide funding to support a Phase 2 Proof of Concept study to explore the effect of vTv Therapeutics' liver-selective glucokinase activator TTP399 as an oral drug for the treatment of T1D. The study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin therapy for people with T1D and can significantly improve daily glucose profiles and HbA1c. JDRF has committed $3M to the study, and vTv will contribute an equal amount. TTP399 is an orally available GK activator that is designed to target GK activation only in the liver for superior glucose control. In the liver, GK is a key regulator of glucose metabolism, and its activation has been shown to increase glucose utilization, which in turn lowers blood glucose. In a six-month Phase 2b clinical trial of TTP399 in patients with type 2 diabetes, TTP399 demonstrated a statistically significant reduction in HbA1c levels in all TTP399 dose groups compared with placebo. TTP399 was also found to be well-tolerated without increased incidences of hypoglycemia and hyperlipidemia compared to placebo.